🚀 VC round data is live in beta, check it out!
GlaxoSmithKline Pakistan Valuation Multiples
Discover revenue and EBITDA valuation multiples for GlaxoSmithKline Pakistan and similar public comparables like Cellectis, GC Biopharma, Altimmune, Senores Pharmaceuticals and more.
GlaxoSmithKline Pakistan Overview
About GlaxoSmithKline Pakistan
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.
Founded
2001
HQ
Employees
1.7K
Website
Sectors
Financials (FY)
EV
$420M
GlaxoSmithKline Pakistan Financials
GlaxoSmithKline Pakistan reported last fiscal year revenue of $237M and EBITDA of $65M.
In the same fiscal year, GlaxoSmithKline Pakistan generated $88M in gross profit, $65M in EBITDA, and $36M in net income.
Revenue (LTM)
GlaxoSmithKline Pakistan P&L
In the most recent fiscal year, GlaxoSmithKline Pakistan reported revenue of $237M and EBITDA of $65M.
GlaxoSmithKline Pakistan expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $237M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $88M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA | — | XXX | $65M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 25% | XXX | XXX | XXX |
| Net Profit | — | XXX | $36M | XXX | XXX | XXX |
| Net Margin | — | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GlaxoSmithKline Pakistan Stock Performance
GlaxoSmithKline Pakistan has current market cap of $450M, and enterprise value of $420M.
Market Cap Evolution
GlaxoSmithKline Pakistan's stock price is $1.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $420M | $450M | 0.0% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGlaxoSmithKline Pakistan Valuation Multiples
GlaxoSmithKline Pakistan trades at 1.8x EV/Revenue multiple, and 6.5x EV/EBITDA.
EV / Revenue (LTM)
GlaxoSmithKline Pakistan Financial Valuation Multiples
As of April 19, 2026, GlaxoSmithKline Pakistan has market cap of $450M and EV of $420M.
Equity research analysts estimate GlaxoSmithKline Pakistan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GlaxoSmithKline Pakistan has a P/E ratio of 12.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $450M | XXX | $450M | XXX | XXX | XXX |
| EV (current) | $420M | XXX | $420M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 7.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.8x | XXX | XXX | XXX |
| P/E | — | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 19.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GlaxoSmithKline Pakistan Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GlaxoSmithKline Pakistan Margins & Growth Rates
GlaxoSmithKline Pakistan's revenue in the last fiscal year grew by 8%.
GlaxoSmithKline Pakistan's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
GlaxoSmithKline Pakistan Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GlaxoSmithKline Pakistan Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| GlaxoSmithKline Pakistan | XXX | XXX | XXX | XXX | XXX | XXX |
| Cellectis | XXX | XXX | XXX | XXX | XXX | XXX |
| GC Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Altimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Senores Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GlaxoSmithKline Pakistan M&A Activity
GlaxoSmithKline Pakistan acquired XXX companies to date.
Last acquisition by GlaxoSmithKline Pakistan was on XXXXXXXX, XXXXX. GlaxoSmithKline Pakistan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GlaxoSmithKline Pakistan
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGlaxoSmithKline Pakistan Investment Activity
GlaxoSmithKline Pakistan invested in XXX companies to date.
GlaxoSmithKline Pakistan made its latest investment on XXXXXXXX, XXXXX. GlaxoSmithKline Pakistan invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GlaxoSmithKline Pakistan
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GlaxoSmithKline Pakistan
| When was GlaxoSmithKline Pakistan founded? | GlaxoSmithKline Pakistan was founded in 2001. |
| Where is GlaxoSmithKline Pakistan headquartered? | GlaxoSmithKline Pakistan is headquartered in Pakistan. |
| How many employees does GlaxoSmithKline Pakistan have? | As of today, GlaxoSmithKline Pakistan has over 1K employees. |
| Is GlaxoSmithKline Pakistan publicly listed? | Yes, GlaxoSmithKline Pakistan is a public company listed on Pakistan Stock Exchange. |
| What is the stock symbol of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan trades under GLAXO ticker. |
| When did GlaxoSmithKline Pakistan go public? | GlaxoSmithKline Pakistan went public in 1953. |
| Who are competitors of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan main competitors are Cellectis, GC Biopharma, Altimmune, Senores Pharmaceuticals. |
| What is the current market cap of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan's current market cap is $450M. |
| What is the current revenue of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan's last fiscal year revenue is $237M. |
| What is the current EV/Revenue multiple of GlaxoSmithKline Pakistan? | Current revenue multiple of GlaxoSmithKline Pakistan is 1.8x. |
| Is GlaxoSmithKline Pakistan profitable? | No, GlaxoSmithKline Pakistan is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.